Recursion Pharmaceuticals, Inc. (RXRX)
After hours:
| Previous Close | 9.51 |
| Open | 9.50 |
| Bid | 9.39 x 1800 |
| Ask | 9.44 x 2600 |
| Day's Range | 9.17 - 9.58 |
| 52 Week Range | 4.97 - 16.75 |
| Volume | |
| Avg. Volume | 6,234,654 |
| Market Cap | 2.239B |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.63 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
GuruFocus.comDirector Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals Inc (RXRX)
On May 14, 2024, Blake Borgeson, Director at Recursion Pharmaceuticals Inc (NASDAQ:RXRX), executed a sale of 20,054 shares of the company.
GlobeNewswireRecursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVID
Simply Wall St.Recursion Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
Recursion Pharmaceuticals ( NASDAQ:RXRX ) First Quarter 2024 Results Key Financial Results Revenue: US$13.8m (up 14...
